Genprex (GNPX) News Today → A new way to collect income from stocks (From DTI) (Ad) Free GNPX Stock Alerts $2.21 -0.10 (-4.33%) (As of 04/24/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineGenprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meetingfinance.yahoo.com - April 9 at 8:38 AMGenprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meetingprnewswire.com - April 9 at 8:31 AMGenprex Expands Trial Sites For Reqorsa Therapy-Tecentriq Trial In Small Cell Lung Cancer; Stock Upmarkets.businessinsider.com - April 3 at 2:03 PMGenprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancerprnewswire.com - April 3 at 8:31 AMGenprex: Collaborators Report Positive Preclinical Data With NPRL2 Gene Therapymarkets.businessinsider.com - April 2 at 6:01 PMGenprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery Systemprnewswire.com - April 2 at 8:31 AMGenprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rulesprnewswire.com - March 22 at 4:10 PMGenprex Shares Drop 12% on Latest Stock Offering to Get Proceeds of $5.8Mmarketwatch.com - March 21 at 8:57 AMGenprex Shares Hit 52-Week Low After Direct Offering Pricesmarketwatch.com - March 20 at 12:32 AMGenprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rulesprnewswire.com - March 19 at 1:24 PMGenprex, Inc.: Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rulesfinanznachrichten.de - March 19 at 9:31 AMGenprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rulesprnewswire.com - March 19 at 8:36 AMGenprex Granted Korean Patent For Reqorsa Therapy With Anti-PD-1, PD-L1 Antibodiesmarkets.businessinsider.com - March 12 at 10:45 AMGenprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancersfinance.yahoo.com - March 12 at 10:45 AMGenprex (NASDAQ: GNPX) Preclinical Data to be Presented at AACR Annual Meetingtheglobeandmail.com - March 9 at 8:30 AMmarketbeat.com - March 6 at 9:36 AMGenprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meetingprnewswire.com - March 6 at 8:30 AMGenprex (NASDAQ: GNPX) Announces Participation at BIO CEO & Investor Conferencetheglobeandmail.com - February 26 at 10:19 AMGenprex To Expand Non-clinical Program To Study TUSC2, NPRL2markets.businessinsider.com - February 7 at 1:08 PMGenprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaboratorsfinance.yahoo.com - February 7 at 1:08 PMGenprex Shares Climb After First Patient Dosing in Reqorsa-Tagrisso Trialmarketwatch.com - February 6 at 10:04 PMGenprex Launches Phase 2a Reqorsa Trial Expansionmsn.com - February 6 at 9:37 AMGenprex to Present at Upcoming BIO CEO & Investor Conferencefinance.yahoo.com - February 6 at 9:37 AMGenprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancerfinance.yahoo.com - February 5 at 9:20 AMmarketbeat.com - February 2 at 6:00 AMDow Turns Lower; Federal Reserve Keeps Rates Unchangedmsn.com - January 31 at 3:52 PMGenprex to effect 1-for-40 reverse stock split to regain Nasdaq compliancemsn.com - January 31 at 3:52 PMGenprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024finance.yahoo.com - January 31 at 10:18 AMGenprex, Inc.: Genprex Provides Business Update and Outlook for 2024finanznachrichten.de - January 5 at 3:49 PMGenprex Provides Business Update and Outlook for 2024finance.yahoo.com - January 5 at 9:37 AMGenprex Granted Orphan Drug Designation in Small Cell Lung Cancerfinance.yahoo.com - November 23 at 12:43 PMGenprex, Inc. (GNPX) stock price, news, quote & history – Yahoo Financenz.finance.yahoo.com - November 16 at 1:47 PMGenprex to Present at BIO-Europe 2023finance.yahoo.com - November 3 at 10:27 AMGenprex to Present at BIO-Europe 2023 Conferencefinance.yahoo.com - November 1 at 12:28 PMGenprex Schedules, Hosts Virtual Key Opinion Leader Eventfinance.yahoo.com - October 20 at 5:46 PMGenprex to Host a Virtual Key Opinion Leader Event on "Bringing Gene Therapy to the Fight Against Lung Cancers"finance.yahoo.com - October 20 at 7:45 AMGenprex to Unveil Encouraging Data on REQORSA(R) at AACR-NIH-EORTC Conferencefinance.yahoo.com - October 6 at 10:20 AMGenprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeuticsfinance.yahoo.com - October 4 at 3:21 PMGenprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLCfinance.yahoo.com - September 21 at 1:20 PMNetworkNewsWire: Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformationfinanznachrichten.de - September 20 at 9:51 AMGenprex to Present at Upcoming H.C. Wainwright Conferencefinance.yahoo.com - September 8 at 8:16 PMGENPREX (GNPX) Upgraded to Buy: Here's What You Should Knowfinance.yahoo.com - September 4 at 6:25 PMGenprex Secures Patent Protection in 'Some of the Most Important Markets in the World'finance.yahoo.com - September 2 at 1:47 AMGenprex Appoints Regulatory Expert as It Drives Clinical Programs Forwardfinance.yahoo.com - August 24 at 5:25 AMGenprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairsfinance.yahoo.com - August 22 at 3:24 PMGenprex Granted FDA Orphan Drug Designation for REQORSA(R) for SCLCfinance.yahoo.com - August 13 at 5:09 PMGenprex (NASDAQ: GNPX) Secures Chinese Patent, Exclusivity for REQORSA(R) Gene Therapy Combinationmsn.com - August 5 at 10:58 PMGenprex Inc. (NASDAQ: GNPX) Closes on $7.5M Registered Direct Offeringmsn.com - August 5 at 10:58 PMGenprex (NASDAQ: GNPX) Enters Exclusive License Agreement with University of Pittsburghmsn.com - August 5 at 5:57 PMGenprex Secures Exclusivity for REQORSA(R)-Keytruda(R) Drug Combination in Chinafinance.yahoo.com - July 28 at 8:50 PM Get Genprex News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet. See how you can invest alongside him GNPX Media Mentions By Week GNPX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GNPX News Sentiment▼0.000.43▲Average Medical News Sentiment GNPX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GNPX Articles This Week▼01▲GNPX Articles Average Week Get Genprex News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PCSA News Today ZVSA News Today LIPO News Today THAR News Today KTRA News Today ARTL News Today ENSC News Today BPTS News Today KZIA News Today VRPX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GNPX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American Alternative1970’s computer coder issues shocking A.I. warningTradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genprex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
